What Diomics does

Diomics is a Carlsbad, California-based for-profit private biotechnology company founded in 2009 that develops therapeutic applications centered on a proprietary polymer it brands "Diomat," targeted at cell therapy use cases. The company operates with a small team (11-50 employees) under a leadership structure consisting of a Chairman (Kirk Avery), a President and Chief Operating Officer (Paul Wolff), and a Chief Science Officer (Eric J. Mathur), consistent with a lean specialty-materials biotech rather than a fully integrated clinical-stage organization.

The company's economic footprint is thin in the public record: four funding events in 2014 represent the entirety of disclosed capital raises (totaling approximately $2.96M), with no investors, lead backers, or valuation disclosed. No products, pricing, partnerships, customers, certifications, patents, clinical milestones, or distribution channels appear in the available data. The only substantive public-facing artifact is the company's primary domain, Diomics.com, which is presently listed for sale by the third-party reseller HugeDomains at $12,295 — an unusual signal for an operating company and the strongest data point currently available about its commercial posture.

Because Diomics has not disclosed revenue, customers, or commercial agreements, the business model cannot be characterized with confidence beyond a preclinical R&D posture. The combination of dated funding, small headcount, absent commercial disclosures, and a domain listed for sale indicates a low level of observable operating activity; any assessment of revenue, growth, or strategic direction from this point forward should be treated as speculative and grounded primarily in the absence of contrary evidence.

Name

Diomics

Website

https://diomics.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

Diomics is a Carlsbad, California-based private biotech founded in 2009 that develops therapeutic applications of its proprietary Diomat polymer for cell therapy, operating with a small (11-50 employee) team and no disclosed commercial revenue or recent funding activity.

Ownership category

akta.pro rank

Product category

Biomaterials and Therapeutic Polymers

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industries

Laboratory Consumables & Plasticware (Tips, Tubes, Plates, Filters) (HLAGAIAH), Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Biomaterials development
• Cell therapy polymers
• Therapeutic polymer platforms
• Biopolymer therapeutics
• Regenerative medicine materials

Headquarters

HQ city

Carlsbad

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Core offering

Diomics develops therapeutic applications of its proprietary Diomat polymer for cell therapy. The company is engaged in biomaterials research and development, focusing on polymer-based substrates and platforms that support cell-based therapeutic use cases for medical and life-science customers.

Product overview

The source data is from a third-party domain resale listing (HugeDomains) selling the domain name Diomics.com. No substantive information about Diomics' actual product or service offerings, company operations, technology platform, or business model is available from this domain sale page.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights1 record

Broad incumbents

• Corning Life Sciences: Corning supplies cell culture surfaces, vessels, and biomaterials used in cell therapy manufacturing. Comparable as a supplier of polymer- and surface-chemistry platforms that enable therapeutic cell workflows, similar in concept to Diomics' Diomat polymer for cell therapy.
• Thermo Fisher Scientific: Through its cell therapy and bioprocessing portfolio, Thermo Fisher supplies materials, media, and instruments used in therapeutic cell manufacturing. Comparable as a broad incumbent serving cell therapy developers with enabling polymer- and consumable-based platforms.
• Lonza: Lonza is a major CDMO offering cell therapy manufacturing services and process development, including media and process consumables. Comparable as an incumbent serving cell therapy developers with enabling materials and platform infrastructure.
• Cytiva: Cytiva (a Danaher company) supplies cell therapy process tools, single-use technologies, and biomaterials. Comparable as an incumbent in enabling polymer and single-use platforms for therapeutic cell production.
• Becton, Dickinson and Company (BD): BD offers cell therapy manufacturing solutions including cell sorting, processing, and single-use polymer consumables. Comparable as a broad incumbent with polymer- and tool-based platforms for therapeutic cell workflows.
• Sartorius: Sartorius supplies bioprocess technologies, including single-use polymer systems and cell therapy manufacturing platforms. Comparable as a broad incumbent enabling therapeutic cell production through polymer and consumable platforms.

Direct peers

• Miltenyi Biotec: Miltenyi Biotec develops cell processing reagents, instruments, and proprietary technologies (e.g., CliniMACS) used in cell therapy manufacturing. Comparable as a direct peer offering specialized tools and platforms for therapeutic cell applications.
• RoosterBio: RoosterBio supplies human mesenchymal stem cell platforms and bioprocess media for cell therapy developers. Comparable as a focused platform-tools provider enabling therapeutic cell manufacturing.
• Pluristyx: Pluristyx offers iPSC-based cell therapy platforms and related tools/services for therapeutic cell developers. Comparable as an emerging platform peer addressing cell therapy manufacturing and development needs.
• OrganaBio: OrganaBio supplies cell and tissue products plus bioprocessing services for cell therapy developers. Comparable as a focused supplier of starting materials and platform tools for therapeutic cell programs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diomics